Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms [RNA-seq]

ABSTRACT: In order to identify GATA-3 target genes in T-cell lymphoproliferative neoplasms, we performed GATA-3 ChIP-seq on 3 cutaneous T-cell lymphoma (CTCL) and 4 T-cell acute lymphoblastic leukemia (T-ALL). We have also established cell lines in which GATA-3 was knocked down by shRNA.

ORGANISM(S): Homo sapiens

PROVIDER: GSE201742 | GEO | 2022/04/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms [ChIP-seq]

Project description:In order to identify GATA-3 target genes in T-cell lymphoproliferative neoplasms, we performed GATA-3 ChIP-seq on 3 cutaneous T-cell lymphoma (CTCL) and 4 T-cell acute lymphoblastic leukemia (T-ALL). We have also established cell lines in which GATA-3 was knocked down by shRNA.

2022-04-30 | GSE201743 | GEO

GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms.

Project description:GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms.

| PRJNA832809 | ENA

GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms [ChIP-seq]

Project description:GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms [ChIP-seq]

| PRJNA832810 | ENA

GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms [RNA-seq]

Project description:GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms [RNA-seq]

| PRJNA832811 | ENA

GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms.

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-04-30 | GSE201744 | GEO

Role of GATA-2 -77 enhancer in murine blood progenitor cells

Project description:We discovered enhancers that control GATA-2 expression during mouse development and in adult and generated mutant mouse strains that lack these enhancers, and these mice have very specific and important phenotypes that revealed GATA-2 mechanisms to control stem and progenitor cell transitions. In this study we aim to determine what proteins are under control of the GATA-2 -77 enhancer in a pool of heterogeneous blood progenitor cells with the specific focus on Socs2 expression.

2020-06-05 | PXD013855 | Pride

HDAC Inhibitors Impair GATA-3 DNA Binding and Target Gene Expression in T-cell Neoplasms

Project description:To investigate early transcriptional changes upon HDACi treatment, a well characterized and p53-deficient CTCL cell line (H9) and primary malignant T cells isolated from the peripheral blood of Sezary Syndrome (SS) patients (n=3) were cultured for 6 hours in the presence of vehicle control, romidepsin (romi) or belinostat (beli) and transcriptionally profiled by RNA-seq

2023-01-31 | GSE219065 | GEO

ChIP seq for GATA-1 and HDAC1 in G1E cells with wild type GATA-1 or mutant

Project description:The transcription factor GATA-1 is essential for erythroid and megakaryocytic cell differentiation and maturation. Previous reports show that GATA-1 is modulated through acetylation modification and through FOG-1 mediated indirect intereaction with HDAC1/2 containing NuRD corepressor complexes. In this study, we found that NuRD does not deacetylate GATA-1. However, HDAC1 alone can efficiently deacetylates GATA-1 and the direct interaction of HDAC1 and GATA-1 is required for the deacetylation. Two arginines within GATA-1 linker region are important for this interaction and arginine to alanine mutations (2RA mutant) largely reduces GATA-1 binding to HDAC1 in FOG-1 independent manner. GATA-1 2RA mutant were then introduced into G1E cells, a GATA-1-null erythroid progenitor cells. The 2RA mutant is acetylated but fails to induce erythroid differentiation. Gene expression analysis shows that GATA-1 2RA mutant affects GATA-1 function in both GATA-1 activated and repressed genes. The gene expression pattern partially overlap with gene expression profile of GATA-1V205M, a GATA-1 mutant with defective FOG-1 binding. ChIP-seq analysis further reveal that 2RA mutation largely reduced GATA-1 chromatin binding, most profoundly at gene promoter regions. HDAC1 recruitment on those promoters are also strongly reduced. These results revealed that GATA-1 recruits HDAC1 to GATA-1 regulated gene promoters and HDAC1 is required for GATA-1 mediated transcription regulation.

2021-09-29 | GSE161608 | GEO

GATA-2 controls megakaryocyte proliferation

Project description:Downregulation of GATA-2 in megakaryocytic cells G1ME caused cell cycle arrest. To identify GATA-2 target genes, we transduced G1ME cells with control vector or a vector expressing shRNA specific for mouse GATA-2. The transduced cells were purified by sorting and the RNA were used for microarry.

2009-06-10 | GSE16521 | GEO

Using global proteomics to investigate the effect of IQDMA treatment on Leukemic forms of cutaneous T-cell lymphomas (L-CTCL) cells

Project description:Leukemic cutaneous T-cell lymphomas (L-CTCL) are lymphoproliferative disorders of skin-homing mature T-cells causing chronic inflammation, tissue destruction, severe infections and sepsis, all linked to poor quality of life and high mortality. Despite numerous sequencing efforts in L-CTCL, recurrent driver mutations have not been identified, but chromosomal losses and gains are frequent and dominant. We integrated genomic landscape analysis with innovative pharmacologic interference studies to identify key vulnerable nodes in L-CTCL. In order to examine IQDMA-specific effects in an unbiased and dose-dependent manner without limiting the analysis to only kinases, we carried out global proteomics profiling in SeAx cells after 24 h treatment with 1, 2.5 and 10 µM IQDMA. The differential proteins affected in response to increasing IQDMA concentrations were found to be related to multiple cellular processes in metabolism, ribosomal RNA processing/modification, protein translation, and surprisingly keratinization.. Dual inhibition of STAT3/5 using small molecule degraders abolished L-CTCL cell growth in vitro. Furthermore, upstream broad range kinase targeting through IQDMA, a newly classified multi-kinase inhibitor, revealed a pharmacologic opportunity to alternatively block the STAT3/5 pathway by inhibiting the PAK2 serine/threonine kinase, which was very effective in patient cells carrying STAT3/5 copy number gains and in vivo in reducing tumor growth and disease dissemination in an intradermal xenograft mouse model. In summary, we conclude that STAT3/5 and PAK2 are new therapy targets to be further explored in L-CTCL.

2022-10-06 | PXD035699 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data